TrialDiabetes, obesity & metabolism2019

Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.

Claire C J Dekkers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.